Product claims may differ from country to country based on regulations and product approvals. Please contact your country representative for further details.

»  Suche

 


Erweiterte Suche



»  News-Alert

Sie möchten über die neuesten Nachrichten und wichtigsten Termine der B·R·A·H·M·S Aktiengesellschaft Informiert werden? Dann tragen Sie sich einfach in unser kostenloses News-Alert-System ein.


Eintragen / Abmelden




Thermo Fisher Scientific PCT Assay for Sepsis Available for Abbott Analyzers More Patients will Benefit from Earlier Detection

Erstellt am: 30.01.2012

WALTHAM, Mass., (January 30, 2012) – Thermo Fisher Scientific, the world leader in serving science, today announced an agreement with global healthcare provider Abbott Laboratories to make its Procalcitonin (PCT) assay available with Abbott’s immunochemistry analyzers.

The company’s Thermo Scientific B•R•A•H•M•S Procalcitonin (PCT) assay will be available on Abbott’s ARCHITECT® “i” and “ci” series of immunochemistry analyzers. Abbott’s high-, medium-, and low-volume integrated diagnostic testing solutions leverage software, reagents, and sample carrier to enable labs to standardize lab operations on a single platform. In turn, laboratories are able to optimize processes, minimize errors and reduce result variability, an increasingly important consideration as clinicians rely more heavily on laboratory diagnostics to guide their treatment decisions.

“Earlier diagnosis of sepsis and other healthcare associated infections can significantly lower healthcare costs and, most important, improve patient outcomes,” said Ken Berger, senior vice president of Thermo Fisher Scientific’s specialty diagnostics business, “Our agreement with Abbott makes it possible for more hospitals and laboratories globally to adopt a proven PCT testing regimen that benefits patients and the entire healthcare industry.”

Thermo Fisher will manufacture the Abbott ARCHITECT B•R•A•H•M•S PCT assay and has exclusive distribution rights in relevant European markets.

Severe sepsis strikes more than 750,000 Americans each year, and between 28 to 50 percent of patients die within the first month of diagnosis. Hospital costs to treat severe sepsis in the U.S. are estimated at $16 billion dollars annually. Much of this cost is attributed to misdiagnosis or delayed diagnosis, making faster, more accurate detection a national, if not global, imperative.  Research published in Critical Care Medicine showed that each hour of delay in therapy can decrease chances of patient survival by 7.6 percent.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.

Zurück zur Übersicht